Viridian Therapeutics, Inc.
VRDN
$20.99
-$0.82-3.76%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.17% | 0.00% | 0.00% | 19.44% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.17% | 0.00% | 0.00% | 19.44% | 0.00% |
| Cost of Revenue | 54.16% | -13.93% | 49.13% | -- | 1,268.89% |
| Gross Profit | -54.22% | 14.08% | -49.15% | 19.44% | -1,291.54% |
| SG&A Expenses | 25.83% | 13.83% | -52.77% | -31.10% | -16.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.86% | 67.84% | 22.35% | 62.91% | 21.76% |
| Operating Income | -47.90% | -67.93% | -22.38% | -62.97% | -21.78% |
| Income Before Tax | -54.99% | -79.04% | -19.24% | -60.91% | -18.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -54.99% | -79.04% | -19.24% | -60.91% | -18.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.99% | -79.04% | -19.24% | -60.91% | -18.03% |
| EBIT | -47.90% | -67.93% | -22.38% | -62.97% | -21.78% |
| EBITDA | -48.04% | -68.15% | -22.46% | -63.15% | -21.81% |
| EPS Basic | -29.72% | -46.86% | -175.36% | -5.75% | 39.16% |
| Normalized Basic EPS | -21.30% | -34.47% | 25.97% | -5.81% | 20.05% |
| EPS Diluted | -29.72% | -46.86% | -175.36% | -5.75% | 39.16% |
| Normalized Diluted EPS | -21.30% | -34.47% | 25.97% | -5.81% | 20.05% |
| Average Basic Shares Outstanding | 27.78% | 33.13% | 61.13% | 52.15% | 47.63% |
| Average Diluted Shares Outstanding | 27.78% | 33.13% | 61.13% | 52.15% | 47.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |